Each day of EHA, we we have written a blog outlining some of the highlights of the research that is pushing the boundaries of our CLL knowledge. The EHA Annual Congress is a forum for original unpublished data, for sharing ideas about hematological innovation and a centre to Communicate, collaborate and network with representatives of a large international audience – medical professionals, national hematology societies, patient groups, medical industry and the media.
Topics in the spotlight from Day 1 of EHA 2018 were wide-ranging and included updates on patient outcomes for already-available treatments, newly-discovered factors of prognostic significance and targets for future drug development.
Day 2 of the 23rd Congress of EHA carried on from where the first day left off with speakers, abstracts and posters covering a diverse range of topics in clinical and translational research in chronic lymphocytic leukaemia (CLL).
The third, and final, day of the scientific programme for the 23rd congress of EHA featured a handful of oral abstracts on chronic lymphocytic leukaemia (CLL). Presentations highlighted some remarkable new clinical and biological research findings.